Description

WHAT IS Tirz—–E?
T———e for weight loss

T———e is a peptide composed of 39 amino acids.

It has been shown to significantly reduce food intake and increase weight loss in clinical trials.

T———e can be defined as the direct successor of the peptide S———e, better known by its commercial name, O—–c. Two years after its introduction to the weight loss medication market, O—–c is already one of the best-selling drugs in the United States — and for good reason: it works. And it also has relatively limited side effects.

But now there is a much more effective option with fewer side effects than O—–c: here we present T———e.

BENEFITS OF T———E

• Induces very significant weight loss in a short time
• Improves insulin sensitivity
• Reduces blood sugar levels
• Has far fewer side effects than other weight loss medications

How do GLP-1 agonists like S———e and T———e work?

S———e (brand name O—–c) and T———e belong to the class of glucagon-like peptide-1 (GLP-1) analog peptides.

GLP-1 is a key ‘incretin’ hormone. Incretin hormones are a group of hormones released in the gastrointestinal tract after eating and stimulate insulin production. These hormones help regulate glucose absorption into the bloodstream and prevent blood sugar spikes after a meal.

GLP-1 not only increases insulin secretion, but also promotes β-cell proliferation and survival, suppresses glucagon secretion, delays gastric emptying, and reduces appetite. All these actions contribute to its antidiabetic and anti-obesity effects. However, GLP-1 has a very short half-life due to its rapid degradation by dipeptidyl peptidase IV and ectopeptidases.

For this reason, several long-acting GLP-1 receptor agonists were developed to achieve optimal results.

Eventually, this process led to the creation and commercialization of S———e (O—–c).
And so, in June 2021, it became the first weight-control drug approved by the FDA since 2014.

Shortly after, in May 2022, the FDA approved the marketing of a new-generation GLP-1 agonist peptide: T———e.

What are the advantages of T———e compared to S———e (O—–c)?

T———e is the only dual agonist of the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor.

In other words, unlike S———e which only acts on GLP-1, T———e acts not only on GLP-1 but also on GIP.

GIP stimulation provides the following benefits:

• Protection against hypoglycemia
• Improves triglyceride clearance and adipose tissue sensitivity to insulin, which can help prevent ectopic fat deposition
• Does not cause as many tolerability issues (nausea, diarrhea…) as S———e, which tends to cause these side effects quite noticeably

Clinical trials comparing T———e and S———e show that T———e is a far superior option in several respects:

• A higher number of patients reach 5%, 10%, and 15% weight loss goals
• Greater absolute and relative reduction in total body weight
• Greater reduction in glycated hemoglobin (HbA1c)
• Fewer tolerability-related side effects

PRODUCT PRESENTATION
Vial containing 5mg of T———e with 99%+ purity.

IMPORTANT: The product label may differ from the one shown in the product image.

HOW TO USE & STANDARD DOSAGE

Reconstitution:
Mix the vial with 2ml of bacteriostatic water.

Initial dose:
2.5 mg (equivalent to 1 ml of liquid) via subcutaneous injection once a week.
For mild overweight, a lower dose of 1.25 mg (equivalent to 0.5 ml of liquid) per week may be used.

After 4 weeks:
If weight loss is insufficient, the dose can be increased to 5 mg (equivalent to 2 ml of liquid) per week.

Once the weight loss goal is achieved, there are two options:

• Discontinue treatment
• Continue treatment with a low maintenance dose of 1.25 mg (equivalent to 0.5 ml of liquid) per week

Maximum dose: 15 mg per week

Duration:

• Minimum 4 weeks to achieve significant results
• No maximum duration. It can be used continuously and safely. The doctor and patient should decide how long it should be used based on the goals defined at the beginning of the treatment.